Combination Therapy for BPH and ED

Guideline-Based Recommendations

The American Urological Association guidelines provide a Moderate Recommendation (Evidence Level: Grade C) that clinicians should not offer the combination of low-dose daily 5mg tadalafil with alpha-blockers for the treatment of LUTS/BPH, due to the lack of added benefit and increased risk of symptomatic hypotension 1, 2, 3
The American Urological Association recommends against combining tadalafil with alpha-blockers, such as alfuzosin, for treating BPH, as it offers no advantages in symptom improvement over either agent alone and increases the risk of symptomatic hypotension 1

For patients with BPH alone, the American Urological Association suggests starting with alfuzosin 10mg once daily as first-line therapy, and if inadequate response after 4-6 weeks, consider adding a 5-alpha-reductase inhibitor, but do not add tadalafil to alfuzosin for BPH treatment 1, 5, 6
For patients with both BPH and ED, the preferred approach is to discontinue alfuzosin and switch to tadalafil 5mg once daily, which treats both conditions with a single medication and avoids drug interaction risks 2, 3

The AUA guidelines prioritize patient safety and real-world clinical outcomes over isolated research results, and recommend against combining alfuzosin and tadalafil for BPH treatment, despite some research suggesting potential benefits 1, 2

The combination of alfuzosin and tadalafil can cause additive blood pressure-lowering effects, leading to symptomatic hypotension, and patients with cardiovascular disease, those taking antihypertensives, or with intravascular volume depletion are at highest risk 1, 3